Pamela Zeitlin
Concepts (482)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystic Fibrosis Transmembrane Conductance Regulator | 45 | 2022 | 348 | 6.650 |
Why?
| | Cystic Fibrosis | 68 | 2022 | 1130 | 5.810 |
Why?
| | Chlorides | 11 | 2020 | 138 | 1.490 |
Why?
| | Chloride Channels | 12 | 2013 | 35 | 1.470 |
Why?
| | Benzodioxoles | 6 | 2022 | 140 | 1.100 |
Why?
| | Bronchi | 9 | 2012 | 267 | 1.030 |
Why?
| | Epithelial Cells | 13 | 2024 | 1114 | 1.020 |
Why?
| | Mutation | 18 | 2022 | 4015 | 0.960 |
Why?
| | Nasal Mucosa | 11 | 2024 | 111 | 0.920 |
Why?
| | Interleukin-8 | 8 | 2017 | 273 | 0.810 |
Why?
| | Phenylbutyrates | 5 | 2006 | 23 | 0.750 |
Why?
| | Alprostadil | 2 | 2013 | 32 | 0.680 |
Why?
| | Indoles | 3 | 2022 | 478 | 0.680 |
Why?
| | Respiratory Mucosa | 8 | 2024 | 331 | 0.630 |
Why?
| | Aminophenols | 6 | 2022 | 176 | 0.620 |
Why?
| | Endoplasmic Reticulum | 9 | 2014 | 265 | 0.560 |
Why?
| | Dependovirus | 5 | 2007 | 77 | 0.550 |
Why?
| | Genetic Therapy | 8 | 2011 | 315 | 0.540 |
Why?
| | Digitoxin | 1 | 2017 | 4 | 0.530 |
Why?
| | Pseudomonas Infections | 5 | 2020 | 230 | 0.520 |
Why?
| | Epithelium | 5 | 2021 | 316 | 0.510 |
Why?
| | Ubiquitin | 2 | 2014 | 73 | 0.500 |
Why?
| | Protein Processing, Post-Translational | 3 | 2014 | 464 | 0.490 |
Why?
| | Lung | 11 | 2022 | 4137 | 0.480 |
Why?
| | Mucociliary Clearance | 3 | 2021 | 45 | 0.480 |
Why?
| | Proteomics | 3 | 2012 | 1138 | 0.460 |
Why?
| | Sputum | 10 | 2020 | 313 | 0.460 |
Why?
| | Proteasome Endopeptidase Complex | 3 | 2014 | 161 | 0.450 |
Why?
| | Sp1 Transcription Factor | 2 | 2006 | 25 | 0.450 |
Why?
| | Anti-Inflammatory Agents | 2 | 2017 | 482 | 0.440 |
Why?
| | Ion Transport | 5 | 2020 | 62 | 0.400 |
Why?
| | Scorpion Venoms | 1 | 2013 | 2 | 0.400 |
Why?
| | Gene Expression Regulation | 7 | 2009 | 2608 | 0.380 |
Why?
| | Protein Array Analysis | 2 | 2012 | 56 | 0.370 |
Why?
| | Cell Line | 11 | 2014 | 2887 | 0.370 |
Why?
| | Pseudomonas aeruginosa | 4 | 2016 | 358 | 0.370 |
Why?
| | Lysine | 1 | 2014 | 292 | 0.360 |
Why?
| | Lubiprostone | 3 | 2022 | 9 | 0.360 |
Why?
| | Humans | 80 | 2024 | 141754 | 0.350 |
Why?
| | NF-kappa B | 4 | 2009 | 692 | 0.330 |
Why?
| | Inflammation | 3 | 2017 | 2902 | 0.330 |
Why?
| | Respiratory System | 3 | 2022 | 157 | 0.330 |
Why?
| | Trachea | 3 | 2008 | 255 | 0.320 |
Why?
| | Quinolones | 4 | 2022 | 174 | 0.310 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2010 | 60 | 0.310 |
Why?
| | Gene Expression Regulation, Developmental | 2 | 2006 | 876 | 0.310 |
Why?
| | Caveolin 1 | 1 | 2009 | 22 | 0.310 |
Why?
| | Aspergillus fumigatus | 1 | 2008 | 25 | 0.290 |
Why?
| | Estrogen Antagonists | 1 | 2008 | 45 | 0.290 |
Why?
| | Endocytosis | 1 | 2009 | 175 | 0.280 |
Why?
| | Dinoprostone | 3 | 2022 | 191 | 0.280 |
Why?
| | Protein Folding | 4 | 2004 | 278 | 0.280 |
Why?
| | Proteome | 4 | 2009 | 485 | 0.280 |
Why?
| | Tamoxifen | 1 | 2008 | 203 | 0.270 |
Why?
| | Calcium | 3 | 2008 | 1192 | 0.270 |
Why?
| | Transcription Factor CHOP | 1 | 2007 | 33 | 0.270 |
Why?
| | Ofloxacin | 1 | 2007 | 17 | 0.260 |
Why?
| | Levofloxacin | 1 | 2007 | 20 | 0.260 |
Why?
| | Drugs, Investigational | 1 | 2007 | 32 | 0.260 |
Why?
| | S-Nitrosoglutathione | 1 | 2006 | 8 | 0.250 |
Why?
| | Mutant Proteins | 1 | 2007 | 102 | 0.250 |
Why?
| | Adolescent | 31 | 2020 | 22130 | 0.250 |
Why?
| | Nebulizers and Vaporizers | 2 | 2005 | 68 | 0.250 |
Why?
| | Heparan Sulfate Proteoglycans | 1 | 2006 | 25 | 0.250 |
Why?
| | Interleukin-13 | 2 | 2024 | 149 | 0.240 |
Why?
| | Pneumonia, Bacterial | 1 | 2007 | 117 | 0.240 |
Why?
| | Membrane Potentials | 5 | 2013 | 284 | 0.240 |
Why?
| | Genetic Testing | 1 | 2008 | 463 | 0.240 |
Why?
| | Adult | 34 | 2022 | 39391 | 0.230 |
Why?
| | Chloride Channel Agonists | 2 | 2021 | 99 | 0.230 |
Why?
| | Aerosols | 2 | 2005 | 181 | 0.230 |
Why?
| | Water | 1 | 2008 | 466 | 0.230 |
Why?
| | Sinusitis | 3 | 2020 | 239 | 0.230 |
Why?
| | Estradiol | 1 | 2008 | 528 | 0.230 |
Why?
| | Respiratory Function Tests | 6 | 2021 | 560 | 0.230 |
Why?
| | Proteins | 3 | 2012 | 1015 | 0.220 |
Why?
| | Positive-Pressure Respiration | 1 | 2005 | 107 | 0.220 |
Why?
| | Anti-Bacterial Agents | 6 | 2014 | 1866 | 0.220 |
Why?
| | Homeostasis | 1 | 2008 | 636 | 0.220 |
Why?
| | Antibodies, Monoclonal | 1 | 2012 | 1474 | 0.220 |
Why?
| | Pyrrolidines | 2 | 2022 | 111 | 0.210 |
Why?
| | Curcumin | 1 | 2004 | 29 | 0.210 |
Why?
| | Lectins | 1 | 2024 | 46 | 0.210 |
Why?
| | GPI-Linked Proteins | 1 | 2024 | 78 | 0.210 |
Why?
| | Flavonoids | 1 | 2004 | 85 | 0.210 |
Why?
| | Mucin 5AC | 1 | 2024 | 70 | 0.210 |
Why?
| | Mucus | 1 | 2024 | 78 | 0.200 |
Why?
| | Plicamycin | 1 | 2003 | 3 | 0.200 |
Why?
| | Dose-Response Relationship, Drug | 8 | 2017 | 2064 | 0.200 |
Why?
| | Genetic Vectors | 5 | 2005 | 336 | 0.200 |
Why?
| | Membrane Proteins | 2 | 2006 | 1158 | 0.190 |
Why?
| | Immunity, Innate | 1 | 2009 | 852 | 0.190 |
Why?
| | Forced Expiratory Volume | 6 | 2018 | 484 | 0.190 |
Why?
| | Amniotic Fluid | 1 | 2003 | 79 | 0.190 |
Why?
| | Female | 39 | 2020 | 75943 | 0.190 |
Why?
| | Signal Transduction | 4 | 2022 | 5169 | 0.190 |
Why?
| | Receptors, Prostaglandin E, EP2 Subtype | 1 | 2022 | 7 | 0.190 |
Why?
| | Peptides, Cyclic | 1 | 2004 | 266 | 0.180 |
Why?
| | Male | 37 | 2020 | 70179 | 0.180 |
Why?
| | Heterozygote | 2 | 2021 | 308 | 0.180 |
Why?
| | Cell Cycle Proteins | 1 | 2006 | 632 | 0.180 |
Why?
| | Prostaglandins | 1 | 2022 | 101 | 0.180 |
Why?
| | Biological Transport | 3 | 2008 | 410 | 0.180 |
Why?
| | Animals | 19 | 2022 | 37749 | 0.170 |
Why?
| | Oxadiazoles | 2 | 2014 | 35 | 0.170 |
Why?
| | Child | 26 | 2024 | 22414 | 0.170 |
Why?
| | Pyrazoles | 2 | 2022 | 482 | 0.170 |
Why?
| | Epithelial Sodium Channels | 1 | 2021 | 21 | 0.170 |
Why?
| | Pyridines | 2 | 2022 | 557 | 0.170 |
Why?
| | Aminopyridines | 2 | 2021 | 109 | 0.170 |
Why?
| | Quinolines | 1 | 2021 | 172 | 0.160 |
Why?
| | Nanoparticles | 3 | 2011 | 484 | 0.160 |
Why?
| | Protein Structure, Tertiary | 2 | 2014 | 859 | 0.160 |
Why?
| | Tobramycin | 4 | 2014 | 52 | 0.160 |
Why?
| | Antibodies, Viral | 2 | 2003 | 656 | 0.160 |
Why?
| | Protein Transport | 3 | 2014 | 448 | 0.150 |
Why?
| | Ergocalciferols | 2 | 2010 | 13 | 0.150 |
Why?
| | Asthma | 2 | 2024 | 1920 | 0.150 |
Why?
| | Paranasal Sinuses | 1 | 2020 | 84 | 0.150 |
Why?
| | Ataxia Telangiectasia | 2 | 2010 | 19 | 0.150 |
Why?
| | Molecular Chaperones | 3 | 2008 | 198 | 0.150 |
Why?
| | Mice | 10 | 2022 | 18109 | 0.150 |
Why?
| | Pulmonary Medicine | 2 | 2010 | 83 | 0.150 |
Why?
| | Cyclic AMP | 3 | 2008 | 219 | 0.150 |
Why?
| | Double-Blind Method | 6 | 2017 | 1989 | 0.150 |
Why?
| | Genotype | 6 | 2021 | 1866 | 0.150 |
Why?
| | Immunoglobulin G | 1 | 2003 | 900 | 0.140 |
Why?
| | Administration, Intranasal | 4 | 2007 | 92 | 0.140 |
Why?
| | Subcellular Fractions | 2 | 2008 | 78 | 0.140 |
Why?
| | Administration, Inhalation | 8 | 2007 | 594 | 0.140 |
Why?
| | Sweat | 4 | 2016 | 47 | 0.140 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2020 | 226 | 0.140 |
Why?
| | Cell Membrane | 2 | 2014 | 724 | 0.140 |
Why?
| | Vitamins | 2 | 2010 | 184 | 0.140 |
Why?
| | Membrane Transport Modulators | 1 | 2017 | 7 | 0.130 |
Why?
| | Biomarkers | 4 | 2017 | 4190 | 0.130 |
Why?
| | Respiratory Tract Infections | 3 | 2008 | 385 | 0.130 |
Why?
| | Aldehyde Oxidoreductases | 1 | 2017 | 27 | 0.130 |
Why?
| | Vitamin D Deficiency | 2 | 2010 | 190 | 0.130 |
Why?
| | Maryland | 1 | 2017 | 63 | 0.130 |
Why?
| | Lung Diseases | 1 | 2003 | 793 | 0.130 |
Why?
| | Rifampin | 1 | 2017 | 89 | 0.130 |
Why?
| | Leukocyte Count | 1 | 2017 | 328 | 0.120 |
Why?
| | Mice, Knockout | 3 | 2009 | 3071 | 0.120 |
Why?
| | Adenosine Triphosphate | 2 | 2008 | 492 | 0.120 |
Why?
| | DNA-Binding Proteins | 1 | 2003 | 1485 | 0.120 |
Why?
| | Computational Biology | 2 | 2012 | 664 | 0.110 |
Why?
| | Drug Combinations | 3 | 2022 | 368 | 0.110 |
Why?
| | Transcription Factors | 1 | 2003 | 1712 | 0.110 |
Why?
| | Gene Transfer Techniques | 3 | 2005 | 176 | 0.110 |
Why?
| | Cell Line, Transformed | 2 | 2006 | 145 | 0.110 |
Why?
| | Young Adult | 9 | 2020 | 13749 | 0.110 |
Why?
| | Drug Design | 2 | 2007 | 168 | 0.110 |
Why?
| | Sodium Chloride | 2 | 2005 | 140 | 0.110 |
Why?
| | Child, Preschool | 11 | 2021 | 11512 | 0.110 |
Why?
| | Ubiquitination | 1 | 2014 | 107 | 0.110 |
Why?
| | Aspergillosis, Allergic Bronchopulmonary | 2 | 2016 | 11 | 0.100 |
Why?
| | Amiloride | 2 | 2004 | 27 | 0.100 |
Why?
| | Exocrine Pancreatic Insufficiency | 2 | 2016 | 23 | 0.100 |
Why?
| | Protein Stability | 1 | 2014 | 175 | 0.100 |
Why?
| | Cells, Cultured | 4 | 2021 | 4212 | 0.100 |
Why?
| | Proteolysis | 1 | 2014 | 175 | 0.100 |
Why?
| | Isoproterenol | 2 | 2004 | 101 | 0.100 |
Why?
| | Mass Spectrometry | 2 | 2014 | 740 | 0.100 |
Why?
| | Pediatrics | 3 | 2010 | 1100 | 0.100 |
Why?
| | Promoter Regions, Genetic | 3 | 2009 | 1243 | 0.100 |
Why?
| | Phenotype | 6 | 2016 | 3177 | 0.100 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 3 | 2009 | 112 | 0.090 |
Why?
| | Neutrophils | 2 | 2017 | 1282 | 0.090 |
Why?
| | Colforsin | 2 | 2021 | 48 | 0.090 |
Why?
| | Sleep | 1 | 2019 | 885 | 0.090 |
Why?
| | RNA, Messenger | 4 | 2008 | 2828 | 0.090 |
Why?
| | Down-Regulation | 3 | 2021 | 641 | 0.090 |
Why?
| | Expectorants | 1 | 2011 | 23 | 0.090 |
Why?
| | HEK293 Cells | 1 | 2014 | 737 | 0.090 |
Why?
| | Enzyme Inhibitors | 2 | 2006 | 855 | 0.090 |
Why?
| | Staining and Labeling | 1 | 2012 | 154 | 0.090 |
Why?
| | Age Factors | 2 | 2017 | 3294 | 0.090 |
Why?
| | Protein Conformation | 1 | 2014 | 941 | 0.090 |
Why?
| | Transduction, Genetic | 1 | 2011 | 136 | 0.090 |
Why?
| | Research Personnel | 2 | 2010 | 184 | 0.080 |
Why?
| | Acetylcysteine | 1 | 2011 | 144 | 0.080 |
Why?
| | Mice, Inbred C57BL | 3 | 2013 | 5909 | 0.080 |
Why?
| | Endopeptidases | 1 | 2010 | 86 | 0.080 |
Why?
| | Vital Capacity | 1 | 2011 | 306 | 0.080 |
Why?
| | Cervix Mucus | 1 | 2009 | 1 | 0.080 |
Why?
| | Anhydrides | 1 | 2009 | 18 | 0.080 |
Why?
| | Microbiota | 1 | 2017 | 768 | 0.080 |
Why?
| | Homozygote | 1 | 2010 | 201 | 0.080 |
Why?
| | Membrane Microdomains | 1 | 2009 | 35 | 0.080 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 1 | 2009 | 99 | 0.080 |
Why?
| | Posterior Horn Cells | 1 | 2009 | 10 | 0.080 |
Why?
| | Rats | 4 | 2009 | 5637 | 0.080 |
Why?
| | Synaptosomes | 1 | 2009 | 32 | 0.080 |
Why?
| | Spiperone | 1 | 2008 | 1 | 0.070 |
Why?
| | Models, Molecular | 1 | 2014 | 1604 | 0.070 |
Why?
| | Models, Biological | 2 | 2007 | 1828 | 0.070 |
Why?
| | Microscopy, Confocal | 1 | 2010 | 324 | 0.070 |
Why?
| | Nutrition Assessment | 1 | 2009 | 93 | 0.070 |
Why?
| | Drug Carriers | 1 | 2009 | 127 | 0.070 |
Why?
| | Electric Conductivity | 1 | 2008 | 86 | 0.070 |
Why?
| | Ribosomes | 1 | 2010 | 186 | 0.070 |
Why?
| | Respiratory System Agents | 1 | 2008 | 23 | 0.070 |
Why?
| | Endoscopy | 1 | 2011 | 324 | 0.070 |
Why?
| | Administration, Topical | 1 | 2008 | 150 | 0.070 |
Why?
| | Biopsy | 1 | 2012 | 1083 | 0.070 |
Why?
| | Polyethylene Glycols | 2 | 2011 | 641 | 0.070 |
Why?
| | Malnutrition | 1 | 2009 | 85 | 0.070 |
Why?
| | Codon, Terminator | 2 | 2007 | 25 | 0.070 |
Why?
| | GTP-Binding Protein alpha Subunits, Gs | 1 | 2007 | 9 | 0.070 |
Why?
| | Fibrous Dysplasia, Polyostotic | 1 | 2007 | 8 | 0.070 |
Why?
| | Blotting, Western | 2 | 2007 | 1234 | 0.070 |
Why?
| | Tissue Distribution | 2 | 2005 | 330 | 0.070 |
Why?
| | Statistics, Nonparametric | 2 | 2005 | 434 | 0.070 |
Why?
| | Mice, Transgenic | 1 | 2013 | 2184 | 0.070 |
Why?
| | Adenoviridae | 2 | 2005 | 201 | 0.070 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2007 | 136 | 0.070 |
Why?
| | Cytosol | 1 | 2008 | 230 | 0.070 |
Why?
| | Aminoglycosides | 1 | 2007 | 26 | 0.070 |
Why?
| | Ibuprofen | 1 | 2007 | 83 | 0.060 |
Why?
| | Technology, Pharmaceutical | 1 | 2007 | 30 | 0.060 |
Why?
| | Mannose-Binding Lectin | 1 | 2006 | 21 | 0.060 |
Why?
| | Metabolic Clearance Rate | 1 | 2007 | 116 | 0.060 |
Why?
| | Treatment Outcome | 9 | 2018 | 11181 | 0.060 |
Why?
| | Airway Obstruction | 1 | 2008 | 164 | 0.060 |
Why?
| | Cyclooxygenase 2 | 1 | 2007 | 176 | 0.060 |
Why?
| | Socioeconomic Factors | 1 | 2011 | 1317 | 0.060 |
Why?
| | Kidney Function Tests | 1 | 2007 | 159 | 0.060 |
Why?
| | HSP40 Heat-Shock Proteins | 1 | 2006 | 27 | 0.060 |
Why?
| | Polysaccharide-Lyases | 1 | 2006 | 11 | 0.060 |
Why?
| | DNA Primers | 1 | 2007 | 510 | 0.060 |
Why?
| | Valosin Containing Protein | 1 | 2006 | 8 | 0.060 |
Why?
| | Nutritional Status | 1 | 2009 | 362 | 0.060 |
Why?
| | Tunicamycin | 1 | 2006 | 12 | 0.060 |
Why?
| | Proteasome Inhibitors | 1 | 2006 | 42 | 0.060 |
Why?
| | DNA, Viral | 2 | 2005 | 367 | 0.060 |
Why?
| | Chondroitin Sulfates | 1 | 2006 | 35 | 0.060 |
Why?
| | CHO Cells | 1 | 2006 | 168 | 0.060 |
Why?
| | Technetium Tc 99m Pentetate | 1 | 2005 | 7 | 0.060 |
Why?
| | Luciferases | 2 | 2003 | 150 | 0.060 |
Why?
| | Gamma Cameras | 1 | 2005 | 6 | 0.060 |
Why?
| | Cricetinae | 1 | 2006 | 301 | 0.060 |
Why?
| | Nitric Oxide Synthase | 1 | 2006 | 242 | 0.060 |
Why?
| | Radionuclide Imaging | 1 | 2005 | 120 | 0.060 |
Why?
| | Glycosylation | 1 | 2006 | 163 | 0.060 |
Why?
| | Glutamine | 1 | 2006 | 107 | 0.060 |
Why?
| | Purinergic P2 Receptor Agonists | 1 | 2005 | 6 | 0.060 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 987 | 0.060 |
Why?
| | Deoxycytosine Nucleotides | 1 | 2005 | 13 | 0.060 |
Why?
| | Uridine | 1 | 2005 | 30 | 0.060 |
Why?
| | Adenosine Triphosphatases | 1 | 2006 | 159 | 0.060 |
Why?
| | Spinal Cord Injuries | 1 | 2009 | 232 | 0.060 |
Why?
| | Nerve Tissue Proteins | 1 | 2009 | 605 | 0.060 |
Why?
| | Chronic Disease | 2 | 2008 | 1820 | 0.060 |
Why?
| | Acidosis | 1 | 2006 | 102 | 0.060 |
Why?
| | Precision Medicine | 1 | 2009 | 434 | 0.060 |
Why?
| | Radiopharmaceuticals | 1 | 2005 | 188 | 0.060 |
Why?
| | Polymers | 1 | 2009 | 495 | 0.060 |
Why?
| | DNA | 1 | 2011 | 1444 | 0.050 |
Why?
| | Gene Expression Profiling | 3 | 2006 | 1771 | 0.050 |
Why?
| | Nasal Polyps | 1 | 2004 | 61 | 0.050 |
Why?
| | Particle Size | 1 | 2005 | 404 | 0.050 |
Why?
| | Inhalation Exposure | 1 | 2004 | 108 | 0.050 |
Why?
| | Base Sequence | 1 | 2007 | 2180 | 0.050 |
Why?
| | Drug Administration Schedule | 4 | 2010 | 771 | 0.050 |
Why?
| | Bronchial Provocation Tests | 1 | 2003 | 50 | 0.050 |
Why?
| | Dietary Supplements | 1 | 2008 | 570 | 0.050 |
Why?
| | Transfection | 1 | 2006 | 943 | 0.050 |
Why?
| | Sp3 Transcription Factor | 1 | 2003 | 6 | 0.050 |
Why?
| | Recombinant Fusion Proteins | 2 | 2003 | 674 | 0.050 |
Why?
| | Diuretics | 1 | 2003 | 73 | 0.050 |
Why?
| | Single-Blind Method | 1 | 2004 | 289 | 0.050 |
Why?
| | Biomedical Research | 1 | 2010 | 708 | 0.050 |
Why?
| | Heat-Shock Proteins | 1 | 2004 | 142 | 0.050 |
Why?
| | Protein Denaturation | 1 | 2003 | 73 | 0.050 |
Why?
| | RNA Interference | 1 | 2005 | 469 | 0.050 |
Why?
| | Xanthines | 1 | 2002 | 23 | 0.050 |
Why?
| | Isoflavones | 1 | 2002 | 26 | 0.050 |
Why?
| | 5' Flanking Region | 1 | 2002 | 9 | 0.050 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2002 | 76 | 0.050 |
Why?
| | Sex Factors | 1 | 2008 | 2063 | 0.050 |
Why?
| | Clinical Protocols | 1 | 2004 | 273 | 0.050 |
Why?
| | Biological Transport, Active | 1 | 2002 | 71 | 0.050 |
Why?
| | Genetic Predisposition to Disease | 2 | 2008 | 2375 | 0.050 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 2002 | 156 | 0.050 |
Why?
| | Disease Progression | 3 | 2017 | 2800 | 0.050 |
Why?
| | Carrier State | 1 | 2002 | 71 | 0.050 |
Why?
| | Bronchodilator Agents | 1 | 2003 | 196 | 0.050 |
Why?
| | Dimethyl Sulfoxide | 1 | 2022 | 41 | 0.050 |
Why?
| | 1-Methyl-3-isobutylxanthine | 1 | 2021 | 24 | 0.050 |
Why?
| | Clinical Trials as Topic | 2 | 2004 | 1057 | 0.050 |
Why?
| | Forecasting | 1 | 2003 | 384 | 0.050 |
Why?
| | Aging | 2 | 2003 | 1924 | 0.040 |
Why?
| | Protein Isoforms | 1 | 2003 | 398 | 0.040 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2006 | 1250 | 0.040 |
Why?
| | NIH 3T3 Cells | 1 | 2021 | 149 | 0.040 |
Why?
| | Point Mutation | 1 | 2002 | 237 | 0.040 |
Why?
| | Interferon-gamma | 1 | 2005 | 792 | 0.040 |
Why?
| | Electrophysiology | 1 | 2021 | 217 | 0.040 |
Why?
| | Nitric Oxide | 1 | 2006 | 900 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2004 | 1041 | 0.040 |
Why?
| | Polymorphism, Genetic | 1 | 2024 | 625 | 0.040 |
Why?
| | Genetic Variation | 1 | 2006 | 1000 | 0.040 |
Why?
| | Up-Regulation | 1 | 2004 | 860 | 0.040 |
Why?
| | Anesthesiologists | 1 | 2022 | 65 | 0.040 |
Why?
| | Patient Acceptance of Health Care | 1 | 2008 | 881 | 0.040 |
Why?
| | Anti-Infective Agents | 1 | 2003 | 239 | 0.040 |
Why?
| | Codon, Nonsense | 2 | 2014 | 43 | 0.040 |
Why?
| | Infant | 4 | 2020 | 9843 | 0.040 |
Why?
| | Occupational Exposure | 1 | 2004 | 349 | 0.040 |
Why?
| | Nasal Surgical Procedures | 1 | 2020 | 5 | 0.040 |
Why?
| | Respiration | 1 | 2021 | 210 | 0.040 |
Why?
| | Viscosity | 2 | 2011 | 93 | 0.040 |
Why?
| | Middle Aged | 8 | 2020 | 34647 | 0.040 |
Why?
| | Cell Survival | 1 | 2003 | 1134 | 0.040 |
Why?
| | Animals, Newborn | 1 | 2002 | 870 | 0.040 |
Why?
| | Cytokines | 2 | 2024 | 2100 | 0.040 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2017 | 650 | 0.040 |
Why?
| | Transcription, Genetic | 1 | 2006 | 1487 | 0.040 |
Why?
| | Albuterol | 1 | 2019 | 75 | 0.040 |
Why?
| | Patient Care Team | 1 | 2004 | 673 | 0.040 |
Why?
| | Immunohistochemistry | 1 | 2003 | 1739 | 0.040 |
Why?
| | Spirometry | 1 | 2019 | 260 | 0.040 |
Why?
| | Haplotypes | 1 | 2020 | 499 | 0.040 |
Why?
| | Biological Products | 1 | 2021 | 239 | 0.040 |
Why?
| | Longitudinal Studies | 2 | 2018 | 2938 | 0.030 |
Why?
| | Temperature | 1 | 2021 | 669 | 0.030 |
Why?
| | Drug Monitoring | 2 | 2017 | 399 | 0.030 |
Why?
| | Retrospective Studies | 5 | 2020 | 16374 | 0.030 |
Why?
| | Cytochrome P-450 CYP3A Inducers | 1 | 2017 | 6 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 2019 | 582 | 0.030 |
Why?
| | Biological Availability | 1 | 2017 | 137 | 0.030 |
Why?
| | Bacteria | 1 | 2003 | 881 | 0.030 |
Why?
| | Biphenyl Compounds | 1 | 2017 | 71 | 0.030 |
Why?
| | Seasons | 2 | 2010 | 546 | 0.030 |
Why?
| | DNA, Bacterial | 1 | 2017 | 339 | 0.030 |
Why?
| | Fellowships and Scholarships | 2 | 2010 | 323 | 0.030 |
Why?
| | Pharmacogenetics | 1 | 2017 | 168 | 0.030 |
Why?
| | Drug Interactions | 1 | 2017 | 406 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2003 | 2006 | 0.030 |
Why?
| | China | 1 | 2016 | 220 | 0.030 |
Why?
| | 3' Untranslated Regions | 1 | 2016 | 149 | 0.030 |
Why?
| | Regression Analysis | 1 | 2017 | 1023 | 0.030 |
Why?
| | Case-Control Studies | 2 | 2017 | 3597 | 0.030 |
Why?
| | Exons | 1 | 2016 | 353 | 0.030 |
Why?
| | Bronchiectasis | 1 | 2016 | 113 | 0.030 |
Why?
| | Colony Count, Microbial | 2 | 2005 | 123 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1498 | 0.030 |
Why?
| | Time Factors | 3 | 2010 | 6966 | 0.030 |
Why?
| | Antineoplastic Agents | 1 | 2005 | 2169 | 0.030 |
Why?
| | Polymerase Chain Reaction | 2 | 2007 | 1056 | 0.020 |
Why?
| | Genes, Reporter | 2 | 2005 | 274 | 0.020 |
Why?
| | Prevalence | 2 | 2010 | 2799 | 0.020 |
Why?
| | Polylysine | 1 | 2011 | 17 | 0.020 |
Why?
| | Biopolymers | 1 | 2011 | 33 | 0.020 |
Why?
| | Diffusion | 1 | 2011 | 121 | 0.020 |
Why?
| | Mucins | 1 | 2011 | 75 | 0.020 |
Why?
| | Follow-Up Studies | 2 | 2010 | 5212 | 0.020 |
Why?
| | Plasmids | 1 | 2011 | 365 | 0.020 |
Why?
| | 25-Hydroxyvitamin D 2 | 1 | 2010 | 7 | 0.020 |
Why?
| | CD4-CD8 Ratio | 1 | 2010 | 24 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 2 | 2009 | 2525 | 0.020 |
Why?
| | Calcifediol | 1 | 2010 | 33 | 0.020 |
Why?
| | alpha-Fetoproteins | 1 | 2010 | 40 | 0.020 |
Why?
| | Pregnancy | 1 | 2003 | 7092 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2020 | 2765 | 0.020 |
Why?
| | Accreditation | 1 | 2010 | 93 | 0.020 |
Why?
| | Societies, Scientific | 1 | 2009 | 51 | 0.020 |
Why?
| | Immunoassay | 1 | 2010 | 113 | 0.020 |
Why?
| | Indicator Dilution Techniques | 1 | 2009 | 12 | 0.020 |
Why?
| | Adhesiveness | 1 | 2009 | 20 | 0.020 |
Why?
| | Mice, Inbred CFTR | 1 | 2008 | 5 | 0.020 |
Why?
| | Cross-Sectional Studies | 2 | 2011 | 5697 | 0.020 |
Why?
| | Type C Phospholipases | 1 | 2008 | 73 | 0.020 |
Why?
| | Cohort Studies | 2 | 2011 | 5815 | 0.020 |
Why?
| | Biological Assay | 1 | 2008 | 131 | 0.020 |
Why?
| | Baltimore | 1 | 2008 | 68 | 0.020 |
Why?
| | Small Molecule Libraries | 1 | 2008 | 98 | 0.020 |
Why?
| | Cell Polarity | 1 | 2008 | 140 | 0.020 |
Why?
| | Hospitals, University | 1 | 2008 | 175 | 0.020 |
Why?
| | Drug Discovery | 1 | 2008 | 147 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2010 | 424 | 0.020 |
Why?
| | Career Choice | 1 | 2009 | 233 | 0.020 |
Why?
| | Placebos | 1 | 2007 | 198 | 0.020 |
Why?
| | Models, Animal | 1 | 2009 | 396 | 0.020 |
Why?
| | Quality of Life | 1 | 2019 | 3014 | 0.020 |
Why?
| | Solutions | 1 | 2007 | 168 | 0.020 |
Why?
| | Gentamicins | 1 | 2007 | 52 | 0.020 |
Why?
| | Sulfur Radioisotopes | 1 | 2006 | 15 | 0.020 |
Why?
| | Silver Staining | 1 | 2006 | 17 | 0.020 |
Why?
| | Receptors, Cell Surface | 1 | 2009 | 398 | 0.020 |
Why?
| | Flavoproteins | 1 | 2006 | 8 | 0.020 |
Why?
| | Dual Oxidases | 1 | 2006 | 4 | 0.020 |
Why?
| | Peptide Mapping | 1 | 2006 | 65 | 0.020 |
Why?
| | Salivary Proteins and Peptides | 1 | 2006 | 15 | 0.020 |
Why?
| | Nutrition Surveys | 1 | 2008 | 280 | 0.020 |
Why?
| | Acute Kidney Injury | 1 | 2014 | 820 | 0.020 |
Why?
| | Prospective Studies | 1 | 2018 | 7777 | 0.020 |
Why?
| | Comorbidity | 1 | 2011 | 1664 | 0.020 |
Why?
| | Energy Intake | 1 | 2009 | 513 | 0.020 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2006 | 145 | 0.020 |
Why?
| | Health Care Surveys | 1 | 2008 | 566 | 0.020 |
Why?
| | Cell Membrane Permeability | 1 | 2006 | 82 | 0.010 |
Why?
| | Blotting, Southern | 1 | 2005 | 75 | 0.010 |
Why?
| | Serum | 1 | 2006 | 60 | 0.010 |
Why?
| | Methionine | 1 | 2006 | 159 | 0.010 |
Why?
| | NADPH Oxidases | 1 | 2006 | 140 | 0.010 |
Why?
| | Receptors, Purinergic P2Y2 | 1 | 2005 | 4 | 0.010 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2008 | 431 | 0.010 |
Why?
| | Helper Viruses | 1 | 2005 | 3 | 0.010 |
Why?
| | Burkholderia | 1 | 2005 | 13 | 0.010 |
Why?
| | Pancreatic Elastase | 1 | 2005 | 60 | 0.010 |
Why?
| | Severity of Illness Index | 2 | 2004 | 2903 | 0.010 |
Why?
| | Societies, Medical | 1 | 2009 | 859 | 0.010 |
Why?
| | Nasal Cavity | 1 | 2005 | 62 | 0.010 |
Why?
| | Education, Medical, Graduate | 1 | 2010 | 526 | 0.010 |
Why?
| | Hemoptysis | 1 | 2005 | 37 | 0.010 |
Why?
| | Peroxidase | 1 | 2005 | 182 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2006 | 557 | 0.010 |
Why?
| | Reference Values | 1 | 2006 | 807 | 0.010 |
Why?
| | Kaplan-Meier Estimate | 1 | 2006 | 910 | 0.010 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2004 | 35 | 0.010 |
Why?
| | Quality of Health Care | 1 | 2009 | 658 | 0.010 |
Why?
| | Siblings | 1 | 2004 | 216 | 0.010 |
Why?
| | Syndrome | 1 | 2004 | 378 | 0.010 |
Why?
| | DNA, Recombinant | 1 | 2003 | 48 | 0.010 |
Why?
| | Antibodies | 1 | 2006 | 411 | 0.010 |
Why?
| | Heating | 1 | 2003 | 18 | 0.010 |
Why?
| | Treatment Failure | 1 | 2004 | 354 | 0.010 |
Why?
| | Saline Solution, Hypertonic | 1 | 2003 | 41 | 0.010 |
Why?
| | Survival Analysis | 1 | 2006 | 1320 | 0.010 |
Why?
| | Virus Shedding | 1 | 2003 | 48 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 2006 | 1268 | 0.010 |
Why?
| | Hearing Disorders | 1 | 2002 | 9 | 0.010 |
Why?
| | Probability | 1 | 2004 | 309 | 0.010 |
Why?
| | Dyspnea | 1 | 2005 | 257 | 0.010 |
Why?
| | Logistic Models | 1 | 2008 | 2092 | 0.010 |
Why?
| | Survivors | 1 | 2006 | 504 | 0.010 |
Why?
| | Audiometry | 1 | 2002 | 31 | 0.010 |
Why?
| | Confidence Intervals | 1 | 2003 | 329 | 0.010 |
Why?
| | Electrophoresis, Gel, Pulsed-Field | 1 | 2002 | 24 | 0.010 |
Why?
| | Oropharynx | 1 | 2002 | 45 | 0.010 |
Why?
| | Bronchoscopy | 1 | 2004 | 226 | 0.010 |
Why?
| | Infusions, Intravenous | 1 | 2003 | 417 | 0.010 |
Why?
| | Viremia | 1 | 2003 | 150 | 0.010 |
Why?
| | Oxidative Stress | 1 | 2009 | 1334 | 0.010 |
Why?
| | Embryonic and Fetal Development | 1 | 2002 | 93 | 0.010 |
Why?
| | United States | 2 | 2010 | 15310 | 0.010 |
Why?
| | Genetic Linkage | 1 | 2002 | 288 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2004 | 761 | 0.010 |
Why?
| | Interleukins | 1 | 2003 | 251 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2005 | 1363 | 0.010 |
Why?
| | Gene Rearrangement | 1 | 2002 | 151 | 0.010 |
Why?
| | DNA Mutational Analysis | 1 | 2002 | 398 | 0.010 |
Why?
| | Recurrence | 1 | 2004 | 1111 | 0.010 |
Why?
| | Chi-Square Distribution | 1 | 2002 | 521 | 0.010 |
Why?
| | Prognosis | 1 | 2010 | 4080 | 0.010 |
Why?
| | Pedigree | 1 | 2002 | 511 | 0.010 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 855 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2004 | 1321 | 0.010 |
Why?
| | Gene Expression | 1 | 2006 | 1492 | 0.010 |
Why?
| | Creatinine | 1 | 2002 | 490 | 0.010 |
Why?
| | Safety | 1 | 2002 | 356 | 0.010 |
Why?
| | Interleukin-6 | 1 | 2005 | 792 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 2002 | 962 | 0.010 |
Why?
| | Body Mass Index | 1 | 2009 | 2385 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2005 | 1977 | 0.010 |
Why?
| | Kinetics | 1 | 2004 | 1655 | 0.010 |
Why?
| | Apoptosis | 1 | 2009 | 2576 | 0.010 |
Why?
| | Feasibility Studies | 1 | 2004 | 1027 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2008 | 3356 | 0.010 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2008 | 1406 | 0.010 |
Why?
| | Kidney Diseases | 1 | 2002 | 409 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2008 | 4421 | 0.010 |
Why?
| | Fetus | 1 | 2002 | 802 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2010 | 5974 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2008 | 6289 | 0.010 |
Why?
| | Adenocarcinoma | 1 | 2002 | 896 | 0.010 |
Why?
| | Hospitalization | 1 | 2005 | 2264 | 0.010 |
Why?
| | Risk Assessment | 1 | 2004 | 3508 | 0.010 |
Why?
| | Risk Factors | 1 | 2008 | 10482 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 2002 | 2567 | 0.000 |
Why?
|
|
Zeitlin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|